Moderna, mRNA and bird flu

Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
US health dept providing Moderna $590 mn to speed mRNA bird flu vaccine
US health officials announced Friday they were awarding $590 million to Moderna to develop mRNA vaccines against influenza, including advancing the company's bird flu vaccine, as fears of a new pandemic grow.
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.
HHS invests nearly $600 million in Moderna’s bird flu vaccine development
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect against bird flu, the pharmaceutical company announced Friday.
Moderna gets $590M HHS contract to develop mRNA pandemic flu vaccines
Moderna receives $590M contract from HHS for mRNA-based bird flu vaccine; up 4% in after-hours trading. Read more here.
Moderna shares slide as it slashes revenue forecast
Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
FiercePharma4d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Moderna’s Financial Outlook Dims Amid Vaccine Challenges and Revised Sales Forecasts, Warrants Sell Rating
In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.